ORLADEYOTM (berotralstat) targets and inhibits plasma kallikrein1

In hereditary angioedema (HAE), uncontrolled kallikrein activity causes an overproduction of bradykinin1

Kallikrein activity in untreated hereditary angioedema
Decreasing plasma kallikrein activity with ORLADEYO™

In HAE, uncontrolled plasma kallikrein activity triggers an overproduction of bradykinin, which leads to vasodilation, vascular leakage, and subsequent swelling.

By decreasing plasma kallikrein activity, ORLADEYO prevents the cleavage of HK and subsequent release of bradykinin, ultimately preventing HAE attacks.

Abbreviations: B, bradykinin; factor XIIa, activated factor XII; HK, high-molecular–weight kininogen.